全文获取类型
收费全文 | 2369篇 |
免费 | 274篇 |
国内免费 | 170篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 6篇 |
妇产科学 | 10篇 |
基础医学 | 52篇 |
口腔科学 | 4篇 |
临床医学 | 268篇 |
内科学 | 582篇 |
皮肤病学 | 2篇 |
神经病学 | 11篇 |
特种医学 | 430篇 |
外国民族医学 | 4篇 |
外科学 | 293篇 |
综合类 | 433篇 |
预防医学 | 38篇 |
药学 | 142篇 |
中国医学 | 41篇 |
肿瘤学 | 496篇 |
出版年
2024年 | 10篇 |
2023年 | 51篇 |
2022年 | 115篇 |
2021年 | 146篇 |
2020年 | 129篇 |
2019年 | 83篇 |
2018年 | 112篇 |
2017年 | 149篇 |
2016年 | 168篇 |
2015年 | 174篇 |
2014年 | 189篇 |
2013年 | 169篇 |
2012年 | 162篇 |
2011年 | 171篇 |
2010年 | 135篇 |
2009年 | 160篇 |
2008年 | 110篇 |
2007年 | 104篇 |
2006年 | 96篇 |
2005年 | 95篇 |
2004年 | 53篇 |
2003年 | 49篇 |
2002年 | 34篇 |
2001年 | 31篇 |
2000年 | 32篇 |
1999年 | 16篇 |
1998年 | 17篇 |
1997年 | 9篇 |
1996年 | 8篇 |
1995年 | 12篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 3篇 |
1991年 | 5篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1985年 | 1篇 |
1983年 | 1篇 |
排序方式: 共有2813条查询结果,搜索用时 187 毫秒
31.
【摘要】 目的 探讨经肝动脉化疗栓塞(TACE)联合经皮射频消融术(PRFA)与单独应用经皮射频消融术治疗原发性肝癌的临床疗效。方法 选择2012年3月~2014年3月在我院诊治的肝癌患者90例,随机分为观察组(50例)与对照组(40例)。观察组予以经肝动脉化疗栓塞联合经皮射频消融术,对照组应用经皮射频消融术治疗,观察两组疗效及预后情况。结果 术后1个月两组患者并发症如疼痛、肺部感染、出血、恶心呕吐等发生率差异无统计学意义(P>0.05);两组术后1个月时血清丙氨酸氨基转移酶(ALT)与门冬氨酸氨基转移酶(AST)水平均低于术前(P<0.05),但观察组术后一个月血清ALT和AST值显著低于对照组(P<0.05);观察组与对照组比较能明显提高近期有效率(P<0.05)。结论 两种治疗方案均能有效治疗原发性肝癌,但经肝动脉化疗栓塞联合经皮射融术相对于单独应用经皮射频消融术,在原发性肝癌治疗中具有更高的缓解率,更有利于肝功能的恢复,可减少术后并发症。 相似文献
32.
An estimated rise in liver cancer incidence will increase to 95374 new cases by 2020. Hepatocellular Carcinoma (HCC), the most common primary malignant tumour of the liver, is considered to be the third leading cause of all cancer-related deaths and fifth common cancer worldwide. The reported data shows that the rate of HCC incidence in male population is three to four times higher compared with the female population. In the United States, HCV-induced liver cancer is increasing very fast because of the lack of proper treatment option. There are various treatment strategies available for HCC like liver transplantation, resection, ablation, embolization and chemotherapy still the prognosis is destitute. If the patient is eligible, liver transplantation is the only therapeutic option that may give around 90% survival rate, but the scarcity of liver donor limits its broad applicability. A sudden address is necessary to develop specific drugs, personalized medicine, for HCC. 相似文献
33.
34.
目的评价多模式疼痛管理方案应用于肝动脉化疗栓塞术患者的效果。方法将166例肝动脉化疗栓塞术患者随机分为对照组80例和干预组86例,对照组采用传统疼痛管理策略,干预组采用多模式疼痛管理策略,包括建立医生、护士、药师及疼痛治疗师多学科团队,实施多模式镇痛知识宣教、超前非甾体抗炎药镇痛、局部浸润渗透、静脉自控镇痛泵、疼痛分级护理等措施。结果干预组术后24h内疼痛严重程度、不良反应(恶心呕吐、便秘腹胀)发生率及睡眠质量显著优于对照组(P0.05,P0.01)。结论多模式疼痛管理方案可有效控制肝动脉化疗栓塞术患者术后疼痛,有利于促进术后恢复。 相似文献
35.
36.
目的观察盐酸昂丹司琼口腔崩解片与注射液两种剂型的临床应用情况。方法选取拟行TACE治疗的肝癌患者38例,按随机原则分为A组和B组,各19例。A组在TACE围手术期使用盐酸昂丹司琼口腔崩解片,B组在TACE围手术期使用盐酸昂丹司琼注射液。观察两组术后恶心、呕吐的发生率及输液量的差异。结果 A组的恶心、呕吐的发生率及输液量均显著低于B组。结论盐酸昂丹司琼的两种剂型均可有效地预防和治疗肝癌TACE后的恶心、呕吐,口腔崩解片较注射液更有效、更安全、更便捷。 相似文献
37.
38.
39.
PurposeA meta-analysis aimed to systematically evaluate the safety and efficiency of I125 irradiation stent placement for patients with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT).Materials and methodsThe Cochrane library, PubMed/Medline, EMBASE, CNKI, Wanfang Data and CQVIP were systematically screened out from the earliest to December 2019. The qualities of all included studies were assessed. The primary endpoints were the 6-month, 12-month stent cumulative patency rate and 6-month, 12-month, 24-month overall survival rate while the secondary endpoints were the objective response rate of PVTT, main portal venous pressure changes and treatment-related adverse events. Our meta-analysis was conducted using Stata 12.0 software.ResultsTotally seven studies with 1018 patients were included in the final analysis, in which 602 patients received TACE and I125 irradiation stent placement, and 416 patients in control group underwent TACE and stent placement without endovascular brachytherapy (EVBT). Meta-analysis showed that the I125 irradiation stent improved the cumulative stent patency rates in 6 months [OR = 1.65, 95% CI (1.32–2.05), P < 0.001] and 12 months [OR = 2.55, 95% CI (1.90–3.42), P < 0.001] and the survival rates in 6 months [OR = 1.77, 95% CI (1.41–2.22), P < 0.001], 12 months [OR = 3.14, 95% CI (2.24–4.40), P < 0.001] and 24 months [OR = 7.39, 95% CI (3.55–15.41), P < 0.001]. However, there was no difference in the objective response rate of PVTT [OR = 1.13, 95% CI (0.87–1.48), P = 0.365], main portal venous pressure and the occurrence adverse event [OR = 0.88, CI = 0.72–1.08, P = 0.212] between two groups.ConclusionI125 irradiation stent seems to be more effective in treating hepatocellular carcinoma with portal vein tumor thrombosis. The usage of portal vein stent combined endovascular brachytherapy has the potential to act as an alternative therapy for HCC with PVTT. On account of the limitation of studies included, more studies with high-level evidence, such as RCTs, are requisite to support the above promising results. 相似文献
40.